Gouty arthritis is characterized by intense joint pain due to deposition of uric acid crystals. Symptoms of gouty arthritis include redness and swelling of joints and intense pain. The condition can be treated with the help of medication. Uric acid is deposited either due to its excess intake or body’s inability to process it leading to inflammation of joint sites such as ankles and toes or wrist. Untreated gouty arthritis may damage joints or kidney as excessive accumulation of uric acid crystals would lead to kidney stone, kidney failure. In most cases, it is observed with other metabolic diseases or conditions such as hypertension, obesity, and diabetes.
High prevalence of associated chronic diseases to provide growth to gouty arthritis market
Other comorbidities such as hypertension is often associated with gout. As per study published in Journal of Rheumatology in 2014, around 75% of gouty arthritis patient were reported to be suffering from hypertension. Therefore patients suffering from chronic disease are at high risk of developing gouty arthritis .High prevalence of gouty arthritis is expected to drive the growth for global gouty arthritis market. According to study published in British Medical Journal in 2017, prevalence of gouty arthritis is 1% to 10% globally. Furthermore, factors such as increasing consumption of high protein food worldwide, linked with gouty arthritis and increasing awareness amongst people for early treatment of disease are the factors boosting growth of gouty arthritis market.
However, lack of awareness among the medical fraternity regarding effective treatment of the condition, especially in emerging economies creates a hindrance for gouty arthritis market growth. For instance, there is different opinion on whether to use urate lowering agents in acute gouty arthritis, urate lowering agent lowers serum urate levels for the dissolution of urate crystals, which is done either by reducing the production of serum uric acid or by promoting its excretion. Moreover, high costs associated with treatment therapy in chronic gouty arthritis hinders the growth of gouty arthritis market.
Gouty Arthritis Market Taxonomy
On the basis of Drug Class
- Urate-lowering agents
On the basis of gouty types
- Acute gouty arthritis
- Chronic gouty arthritis
North America holds dominant position in gouty arthritis market
Regional segmentation of gouty arthritis market by Coherent Market Insights consist of North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate gouty arthritis market, owing high prevalence of gouty arthritis in the U.S. According to Centre for Disease Control and Prevention (CDC), an estimated 54.4 million patients annually suffered from some form of arthritis from 2013 - 2015, in which gouty arthritis carries significant share. According to clinical guidelines for gout published in Annals of Internal Medicine in 2017, about 3.9% of U.S. adults older than 20 years reported about gout at least once in lifetime. Furthermore, increasing geriatric population is driving growth of the market, owing to high prevalence of gouty arthritis in patients above 40 years of age. New and effective therapies to treat gouty arthritis are expected to fuel growth of gouty arthritis market. For instance, in 2015, Astra Zeneca received FDA approval for novel molecule lesinurad (Zurampic), lesinurad is a urate transport inhibitor which inhibits URAT1, a protein responsible for reabsorption of uric acid in kidneys, given in combination with xanthine oxidase inhibitor helps achieve target serum uric acid level. Asia Pacific region is gaining significant traction in this market, owing to increasing number of patients suffering from chronic diseases such as diabetes and cardiovascular disease or chronic kidney disease, which are rising incrementally as stated by WHO factsheet 2012,this is owing to established fact that around 75% hypertensive patients had gouty arthritis as study published in Journal of Rheumatology in 2014.
Major players operating in the gouty arthritis market include AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Novartis AG; Savient Pharmaceuticals, GlaxoSmithKline plc, Merck& Co. Inc., Teijin Pharma Ltd., Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, and Nippon Chemiphar Co. Ltd.
- In August 2017, FDA approved first fixed dose combination called Duzallo (Ironwood Pharmaceuticals) of lesinurad with allopurinol to treat hyperuricemia in patients with uncontrolled gout. Duzallo is a one a day combination oral treatment.
- In 2015, Prasco Laboratories and Takeda Pharmaceutical Inc. entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, which is generic version of Colrycs, colchicine brand by Takeda Pharmaceutical Inc., this would strengthen the distribution for colchicine and improve accessibility.
- Novartis in 2013 received European commission approval for Ilaris in treatment of acute gouty arthritis for patients who suffer from frequent attacks of gouty arthritis and are contraindicated to use other treatment option. Illaris is first biologic product to be used in gouty arthritis in Europe.